


Cervix Cancer Research Network (CCRN)

Chair: Mary McCormack

**Steering Committee: Marie Plante,
David Gaffney, Sang Young Ryu, Bill
Small, Jonathan Berek, Carien
Creutzberg, Anuja Jhingran, Linus
Chuang, Linda Mileskin, Al Covens
(IGCS) and Monica Bacon**



- 4th most common cancer women
- Over 500,000 new cases/260,000 deaths per year
- Mortality varies 2-27/100,000
- Cancer burden likely to rise

FIGURE 11. Cervical Cancer Incidence and Mortality Rates by World Area.

Global Cancer Statistics, 2012. CA Cancer J Clin;65-87-108, 2015




Health, equity, and women's cancers 1



The global burden of women's cancers: a grand challenge in global health

Ophira Ginsburg, Freddie Bray, Michel P Coleman, Verna Vanderpuye, Alexandru Eniu, S Rani Kotha, Malabika Sarker, Tran Thanh Huong, Claudia Allemani, Allison Dvaladze, Julie Gralow, Karen Yeates, Carolyn Taylor, Nandini Oomman, Suneeta Krishnan, Richard Sullivan, Dominista Kombe, Magaly M Blas, Groesbeck Parham, Natasha Kassami, Lesong Conteh

Lancet 2017,389






Accelerating cervical cancer elimination

Report by the Director-General

CERVICAL CANCER: A GLOBAL PUBLIC HEALTH PRIORITY

Cervical Cancer






What is CCRN ?


- A Network of centres with expertise in the management of cervical cancer
- Established in 2011 by Prof Henry Kitchner & managed by GCIIG
- These centres are generally in LMIC
- Common goal to promote research and good clinical practice in the treatment of women with cervical cancer
- Recognised that participation in research raises the standards for all patients.
- Inclusion of patients from diverse ethical and cultural backgrounds in clinical trials is essential to validate potentially practice changing approaches.




CCRN background



Current CCRN studies



CCRN standard operating procedure



Resources & Research Capability


- Site information-contacts/ number of new cancers, Gyn ca & Cervix
- Site resources-pathology/radiology/ [IT/ indemnity insurance](#)
- Clinical trials ops-[CTU/Personnel](#) /tumour boards/ [previous trials experience](#)/details of ethics and regulatory approval processes
- Radiation therapy –facilities/documentation/dosimetry audit

CCRN trials-Capability questionnaire

1. Are your clinical trial subjects entitled to medical management without cost as long as required; and entitled to financial compensation for clinical trial related injury or death?
2. Do you have (national) definitions of what constitutes 'clinical trial related injury or death'?
3. Do you follow ICH Good Clinical Practice [GCP] Guidelines?
4. As well as protocol-mandated reporting through the data reporting mechanism, is there a national regulatory procedure for reporting serious adverse events .

Current CCRN sites

Fig. 1. Worldwide incidences of cervical cancer per 100 000 females (all ages), age-standardized to the WHO standard population, 2005⁴



Blue- participating in current trials
Red - CCRN approved
Gold- approved with contingency
Black- pending

Meeting objectives

- Establish new partnerships to further care of women with cervical cancer
- Facilitate the exchange of ideas in developing *new* trials
- Encourage participation in *ongoing* CCRN trials
- Understand HIV & Cervical cancer and its unique challenges

With thanks to our sponsors & supporters.



Gynecologic Cancer InterGroup
Cervix Cancer Research Network

END



Cervix Cancer Education Symposium, February 2018

International clinical trials-Challenges

